Sublineages of Mycobacterium tuberculosis Beijing genotype strains and unfavorable outcomes of anti-tuberculosis treatment

Tuberculosis
Nguyen T L HangHiroyoshi Endo

Abstract

The influence of Mycobacterium tuberculosis (MTB) lineages/sublineages on unfavorable tuberculosis (TB) treatment outcomes is poorly understood. We investigated the effects of Beijing genotype sublineages and other factors contributing to treatment outcome. Patients newly diagnosed with sputum smear-positive and culture-positive TB in Hanoi, Vietnam, participated in the study. After receiving anti-TB treatment, they were intensively followed up for the next 16 months. MTB isolates collected before treatment were subjected to drug susceptibility testing, and further analyzed to determine MTB (sub) lineages and their clonal similarities. Of 430 patients, 17 had treatment failure and 30 had TB recurrence. Rifampicin resistance was associated with treatment failure {adjusted odds ratio = 6.64 [95% confidence interval (CI), 1.48-29.73]}. The modern Beijing genotype was significantly associated with recurrent TB within 16 months [adjusted hazard ratio = 3.29 (95% CI, 1.17-9.27)], particularly after adjustment for the relevant antibiotic resistance. Human immunodeficiency virus coinfection and severity on chest radiographs were not significantly associated with unfavorable outcomes. Our findings provide further understanding of the in...Continue Reading

References

May 18, 2000·JAMA : the Journal of the American Medical Association·M A EspinalM C Raviglione
Jan 15, 2004·Emerging Infectious Diseases·Nguyen Thi Ngoc LanDick van Soolingen
Sep 18, 2004·American Journal of Respiratory and Critical Care Medicine·Kwok C ChangCheuk M Tam
May 18, 2006·Emerging Infectious Diseases·UNKNOWN European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Igor MokrousovA Dong Shen
Jun 16, 2007·The Journal of Infectious Diseases·Jann-Yuan WangPan-Chyr Yang
Jul 16, 2008·Annals of Internal Medicine·Woojin LewDick Menzies
Feb 6, 2009·Emerging Infectious Diseases·Kristin KremerDick van-Soolingen
Jul 25, 2009·Emerging Infectious Diseases·William J BurmanUNKNOWN Tuberculosis Trials Consortium
Jun 1, 2010·The Lancet Infectious Diseases·David J HorneKaren R Steingart
Aug 13, 2011·Tuberculosis·M HanekomR M Warren
Aug 7, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Chongguang YangQian Gao
Dec 20, 2012·Thorax·María Eugenia Jiménez-CoronaAlfredo Ponce-de-León
Feb 15, 2013·The Journal of Infectious Diseases·Mai N T HuyenFrank G J Cobelens
Mar 20, 2013·Annals of the American Thoracic Society·Craig M HalesWilliam J Burman
Jun 24, 2014·The Journal of Infection·Nguyen Thi Le HangNaoto Keicho
Dec 3, 2014·Seminars in Immunology·Mireia Coscolla, Sebastien Gagneux

❮ Previous
Next ❯

Citations

Mar 3, 2020·Wellcome Open Research·James A SeddonUNKNOWN Tuberculous Meningitis International Research Consortium
Jun 28, 2021·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Mei LiuLing Chen
Nov 14, 2020·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·S M Shahriar RizviS M Mostofa Kamal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.